Pipeline
Nuvation Bio is focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed. We are advancing multiple compounds that have been generated from our drug discovery and development programs, which include a clinical stage bromodomain and extra-terminal (BET) inhibitor program and a novel, small molecule drug-drug conjugate (DDC) platform that to date has yielded investigational candidates targeting solid tumors.
Program
potential indication(s)
Current Stage
preclinical
phase 1
Phase 2
Phase 3
ANTICIPATED MILESTONES &
RECENT UPDATES
Advanced
Solid Tumors
NUV-868
First Patient Dosed in Phase 1 Dose Escalation in Q1 2022
NUV-868
(BET)
Ovarian, TNBC,
Pancreatic &
mCRPC
NUV-868 +
Olaparib
Dose First Patient by Year End 2022
mCRPC
NUV-868 +
Enzalutamide
Dose First Patient by Year End 2022
Drug-Drug
Conjugate
Platform
SolidTumors
Select Clinical Candidate by Year End 2022
BET
NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor, inhibits BRD4. BRD4 is a key member of the BET family, which epigenetically regulates proteins that control tumor growth and differentiation.
NUV-868 is almost 1,500 times more selective for BD2 than BD1 and is designed to alleviate the therapeutic limiting toxicities observed by other non-BD2 selective BET inhibitors. NUV-868 in combination with androgen-receptor directed therapies may help to overcome resistance in prostate cancer. In addition, NUV-868 in combination with PARP inhibitors may act synergistically to increase efficacy across multiple solid tumors.
In March 2022, we initiated a Phase 1 dose escalation study of NUV-868 for the treatment of patients with advanced solid tumors and enrollment is ongoing. We expect to initiate the Phase 1b study of NUV-868 in combination with olaparib in ovarian, pancreatic, metastatic castration-resistant prostate and triple negative breast cancers, or in combination with enzalutamide in metastatic castration-resistant prostate cancer, by the end of 2022.
